Trump Signals Imminent Action on Cannabis Rescheduling Initiative

The Trump administration appears ready to advance federal cannabis rescheduling efforts that have stalled since late 2024, according to sources familiar with the matter. The move would represent a major shift in federal cannabis policy and could unlock significant market opportunities for operators across multiple state programs.

Rescheduling cannabis from Schedule I to a lower classification would eliminate the punitive 280E tax provision that prevents cannabis companies from deducting standard business expenses. This change alone could boost industry margins by 15-25% according to financial analysts, providing immediate relief to operators struggling with compressed profitability in oversupplied markets.

The regulatory development comes as cannabis stocks have underperformed broader markets over the past 18 months, with many multi-state operators trading at steep discounts to traditional retail and consumer goods companies. Federal rescheduling could catalyze institutional investment that has remained largely sidelined due to cannabis's current Schedule I status alongside substances like heroin and LSD.

Banking access represents another critical catalyst tied to rescheduling efforts. While the SAFE Banking Act continues to face congressional hurdles, administrative rescheduling could provide banks greater regulatory clarity to serve cannabis businesses without fear of federal enforcement actions. This would reduce operational costs and improve capital access for expansion-focused operators.

The timing aligns with state-level momentum as additional markets prepare to launch adult-use programs throughout 2026. Federal policy changes would create a more favorable environment for interstate commerce discussions and could accelerate consolidation among regional operators seeking to build national footprints ahead of potential federal legalization.